tetano
Editor, Senior Moderator
Microorganisms
. 2021 Dec 13;9(12):2578.
doi: 10.3390/microorganisms9122578.
Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses
Grigore Mihaescu[SUP] 1 [/SUP], Mariana Carmen Chifiriuc[SUP] 1 2 3 [/SUP], Corneliu Ovidiu Vrancianu[SUP] 1 [/SUP], Marian Constantin[SUP] 4 [/SUP], Roxana Filip[SUP] 5 6 [/SUP], Mihaela Roxana Popescu[SUP] 7 [/SUP], Liliana Burlibasa[SUP] 1 [/SUP], Anca Cecilia Nicoara[SUP] 8 [/SUP], Alexandra Bolocan[SUP] 9 [/SUP], Ciprian Iliescu[SUP] 10 11 12 [/SUP], Gratiela Gradisteanu Pircalabioru[SUP] 2 [/SUP]
Affiliations
Abstract
After two previous episodes, in 2002 and 2012, when two highly pathogenic coronaviruses (SARS, MERS) with a zoonotic origin emerged in humans and caused fatal respiratory illness, we are today experiencing the COVID-19 pandemic produced by SARS-CoV-2. The main question of the year 2021 is if naturally- or artificially-acquired active immunity will be effective against the evolving SARS-CoV-2 variants. This review starts with the presentation of the two compartments of antiviral immunity-humoral and cellular, innate and adaptive-underlining how the involved cellular and molecular actors are intrinsically connected in the development of the immune response in SARS-CoV-2 infection. Then, the SARS-CoV-2 immunopathology, as well as the derived diagnosis and therapeutic approaches, will be discussed.
Keywords: SARS-CoV-2; antibodies; antiviral; immune response; inflammation; lymphocytes.
. 2021 Dec 13;9(12):2578.
doi: 10.3390/microorganisms9122578.
Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses
Grigore Mihaescu[SUP] 1 [/SUP], Mariana Carmen Chifiriuc[SUP] 1 2 3 [/SUP], Corneliu Ovidiu Vrancianu[SUP] 1 [/SUP], Marian Constantin[SUP] 4 [/SUP], Roxana Filip[SUP] 5 6 [/SUP], Mihaela Roxana Popescu[SUP] 7 [/SUP], Liliana Burlibasa[SUP] 1 [/SUP], Anca Cecilia Nicoara[SUP] 8 [/SUP], Alexandra Bolocan[SUP] 9 [/SUP], Ciprian Iliescu[SUP] 10 11 12 [/SUP], Gratiela Gradisteanu Pircalabioru[SUP] 2 [/SUP]
Affiliations
- PMID: 34946179
- DOI: 10.3390/microorganisms9122578
Abstract
After two previous episodes, in 2002 and 2012, when two highly pathogenic coronaviruses (SARS, MERS) with a zoonotic origin emerged in humans and caused fatal respiratory illness, we are today experiencing the COVID-19 pandemic produced by SARS-CoV-2. The main question of the year 2021 is if naturally- or artificially-acquired active immunity will be effective against the evolving SARS-CoV-2 variants. This review starts with the presentation of the two compartments of antiviral immunity-humoral and cellular, innate and adaptive-underlining how the involved cellular and molecular actors are intrinsically connected in the development of the immune response in SARS-CoV-2 infection. Then, the SARS-CoV-2 immunopathology, as well as the derived diagnosis and therapeutic approaches, will be discussed.
Keywords: SARS-CoV-2; antibodies; antiviral; immune response; inflammation; lymphocytes.